Domov › Imunski sistem in motnje › Pennsylvania
Klinične študije za Imunski sistem in motnje v Pennsylvania
12 študij za Imunski sistem in motnje išče udeležence na lokacijah v Pennsylvania.
Mesta v Pennsylvania
Uradno besedilo študije (angleško)
A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
- University of Pennsylvania - Abramson Cancer Center, Philadelphia
Vključevanje udeležencevFaza 1
Starost 18 in več · Vsi spoli · Posodobljeno 30. sep. 2026 · NCT07192471A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
- Perelman Center for Advanced Medicine (PCAM) Hospital of The University of Pennsylvania Penn Blood Disorders Program, Philadelphia
- Lewis Katz School of Medicine at Temple University, Philadelphia
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 18. sep. 2026 · NCT06722235Collection of Research Data and Samples From Patients Treated With Immunotherapy to Study Its Side Effects
- Lehigh Valley Hospital-Cedar Crest, Allentown
- Lehigh Valley Hospital - Muhlenberg, Bethlehem
- Christiana Care Health System-Concord Health Center, Chadds Ford
- in še 18
Vključevanje udeležencevOpazovalna študija
Vse starosti · Vsi spoli · Posodobljeno 17. sep. 2026 · NCT04242095A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
- Perelman Center for Advanced Medicine (PCAM) Hospital of The University of Pennsylvania Penn Blood Disorders Program, Philadelphia
- Lewis Katz School of Medicine at Temple University, Philadelphia
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 9. sep. 2026 · NCT06948318Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
- Lehigh Valley Topper Cancer Center Institute, Allentown
- Thomas Jefferson University, Philadelphia
- West Penn Hospital, Pittsburgh
Vključevanje udeležencevFaza 1/2
Starost 18 in več · Vsi spoli · Posodobljeno 25. avg. 2026 · NCT05826535Abatacept for the Treatment of Giant Cell Arteritis
- University of Pennsylvania, Philadelphia
Vključevanje udeležencevFaza 3
Starost 50 in več · Vsi spoli · Posodobljeno 20. avg. 2026 · NCT04474847A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
- Abramson Cancer Center of the University of Pennsylvania, Philadelphia
Vključevanje udeležencevFaza 1/2
Starost 18 in več · Vsi spoli · Posodobljeno 19. avg. 2026 · NCT04104776Evolution of Metabolic and Immune Dysfunction in In-transit Melanoma
- UPMC Hillman Cancer Center, Pittsburgh
Vključevanje udeležencevOpazovalna študija
Starost 18 in več · Vsi spoli · Posodobljeno 11. jun. 2026 · NCT04658303A Study of Treatment of Inflammation Before Stem Cell Transplant in People With a Primary Immune Regulatory Disorder (PIRD) and/or an Autoinflammatory Condition
- Children's Hospital of Philadelphia, Philadelphia
Vključevanje udeležencevFaza 2
Vse starosti · Vsi spoli · Posodobljeno 2. jun. 2026 · NCT05787574A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)
- University of Pennsylvania, Philadelphia
Vključevanje udeležencevFaza 1/2
Starost 18 in več · Vsi spoli · Posodobljeno 29. maj 2026 · NCT04422912CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
- UPMC Hilman Cancer Center, Pittsburgh
Vključevanje udeležencevFaza 1/2
Starost 18 in več · Vsi spoli · Posodobljeno 16. apr. 2026 · NCT03328078A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)
- UPMC Hillman Cancer Center, Pittsburgh
Vključevanje udeležencevFaza 2
Starost 18 in več · Vsi spoli · Posodobljeno 15. dec. 2025 · NCT06619561Vir: ClinicalTrials.gov, podatki pridobljeni 5. okt. 2026. Vsaka študija ima svoje pogoje vključitve; ekipa študije odloči, kdo lahko sodeluje.